Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $7.96, but opened at $8.20. Abivax shares last traded at $8.02, with a volume of 70,080 shares traded.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the company. JMP Securities reiterated a "market outperform" rating and set a $33.00 target price on shares of Abivax in a research note on Wednesday, April 30th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price objective on shares of Abivax in a research note on Thursday, March 20th.
Check Out Our Latest Stock Report on Abivax
Abivax Stock Performance
The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 1.29. The business has a 50 day simple moving average of $6.77 and a two-hundred day simple moving average of $6.70.
Institutional Trading of Abivax
Institutional investors have recently added to or reduced their stakes in the business. Octagon Capital Advisors LP bought a new position in shares of Abivax during the first quarter valued at about $7,688,000. ADAR1 Capital Management LLC boosted its holdings in Abivax by 190.1% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock valued at $11,078,000 after acquiring an additional 991,781 shares in the last quarter. Caligan Partners LP purchased a new stake in shares of Abivax in the 4th quarter worth about $5,506,000. JPMorgan Chase & Co. purchased a new position in shares of Abivax during the fourth quarter valued at about $5,336,000. Finally, Allostery Investments LP bought a new stake in Abivax during the 4th quarter valued at approximately $4,328,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
